P38MAP kinase inhibitor
US8642773B2 · kind B2 · utility
42Cited by
5References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2010 |
| Grant date | Feb 4, 2014 |
| Priority date | — |
| Expiry date | Apr 1, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of formula (I):or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.